Key Insights

Highlights

Success Rate

77% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

8.6%

3 terminated out of 35 trials

Success Rate

76.9%

-9.6% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

90%

9 of 10 completed with results

Key Signals

9 with results77% success

Data Visualizations

Phase Distribution

34Total
Not Applicable (1)
Early P 1 (1)
P 1 (15)
P 2 (16)
P 3 (1)

Trial Status

Recruiting12
Completed10
Active Not Recruiting7
Terminated3
Unknown1
Withdrawn1

Trial Success Rate

76.9%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (35)

Showing 20 of 20 trials
NCT07468916Phase 2Not Yet Recruiting

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

NCT02727803Phase 2Recruiting

Personalized NK Cell Therapy in CBT

NCT04771572Phase 1Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

NCT06661915Phase 2Recruiting

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

NCT04771130Phase 1Recruiting

A Study of BGB-11417 in Participants With Myeloid Malignancies

NCT06599762Phase 2Recruiting

Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

NCT06034470Phase 1Active Not Recruiting

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

NCT05038592Phase 1Active Not Recruiting

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

NCT03289910Phase 2Active Not Recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

NCT05600894Phase 2Active Not Recruiting

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT04902833Active Not Recruiting

Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

NCT04282187Phase 2Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

NCT07270978Phase 1Recruiting

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

NCT06523556Phase 1Recruiting

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT03630991Phase 1Recruiting

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

NCT07228624Phase 2RecruitingPrimary

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

NCT02861417Phase 2Active Not Recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

NCT05875805Not ApplicableRecruiting

A Telehealth Advance Care Planning Intervention

NCT03560752Phase 1Active Not Recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

NCT02158858Phase 1Completed

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Scroll to load more

Research Network

Activity Timeline